Natália Merten Athayde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natália Merten Athayde has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Caio César Diniz Disserol
Universidade Federal do Paraná, Hospital de Clínicas, Curitiba PR, Brazil
1 shared publication - Cleonisio Leite Rodrigues
Hospital Geral de Fortaleza Fortaleza Ceará Brazil
1 shared publication - Denison Alves Pedrosa
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication - Eduardo Braga de Oliveira
Hospital Geral de Fortaleza, Serviço de Neurologia, Fortaleza CE, Brazil
1 shared publication - Hermany Capistrano Freitas
Hospital Geral de Fortaleza, Serviço de Neurologia, Fortaleza CE, Brazil
1 shared publication - José Pedro Soares Baima
Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (06) , 001-005
Optimizing myasthenia gravis management in practice: integrating clinical scales and classification systems
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (06) , 001-005
Open AccessOptimizing myasthenia gravis management in practice: integrating clinical scales and classification systems
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.
- Open Access
- 10 February 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAI0807
Creutzfeldt-Jakob Disease variant presenting with prominent basal ganglia imaging
A 53-years old white women was presented with a four-weeks history of unsteady gait, followed by mental confusion and progressive memory loss. Neurological examination revealed axial ataxia, short-term memory loss, and brisk deep tendon reflexes in all limbs. Brain MRI () revealed a diffusion signal abnormality involving the bilateral caudate heads and putamen, with no cortical changes. Cerebrospinal fuid (CSF) analysis showed 1 cells per μL, protein content of 25.5 mg/dL, and glucose content of 58 mg/dL. Eletroencefalograma revealed no
- 10 February 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAI0807
Open AccessCreutzfeldt-Jakob Disease variant presenting with prominent basal ganglia imaging
A 53-years old white women was presented with a four-weeks history of unsteady gait, followed by mental confusion and progressive memory loss. Neurological examination revealed axial ataxia, short-term memory loss, and brisk deep tendon reflexes in all limbs. Brain MRI () revealed a diffusion signal abnormality involving the bilateral caudate heads and putamen, with no cortical changes. Cerebrospinal fuid (CSF) analysis showed 1 cells per μL, protein content of 25.5 mg/dL, and glucose content of 58 mg/dL. Eletroencefalograma revealed no